Page 172 - Memoria SEHH 2022

MEMORIA ANUAL 2022 SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
GETCC
FUNDACIÓN ESPAÑOLA DE HEMATOLOGÍA Y HEMOTERAPIA
Vives J, Hernández J, Mirabel C, Puigdomenech-Poch M, Romeo-Guitart D, Marmolejo- Martínez-Artesero S, Cabrera-Pérez R, Jaramillo J, Kumru H, García-López J, Vidal-Samsó J, Navarro X, Coll-Bonet R .
• A hub-and-spoke model to deliver effective access to chimeric antigen receptor T-cell therapy in a public health network: the Catalan Blood and Tissue Bank expe- rience.
Cytotherapy. 2023 Jan;25(1):14-9. doi: 10.1016/j.jcyt.2022.07.011.
Fernández-Sojo J, Delgadillo J, Vives J, Rodríguez L, Mendoza A, Azqueta C, García- Buendía A, Valdivia E, Martorell L, Rubio-López N, Linares M, Alonso S, Ancochea A, García-Rey E, García-Muñoz N, Medina L, Querol S .
• Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medici- nes: Good Practice for Better Therapies.
Stem Cells Transl Med. 2022 Aug 23;11(8):805-13. doi: 10.1093/stcltm/szac046. López-Navas L, Torrents S, Sánchez-Pernaute R, Vives J .
• The Quality Management Ecosystem in Cell Therapy in Catalonia (Spain): An Oppor- tunity for Integrating Standards and Streamlining Quality Compliance.
Cells. 2022 Jul 5;11(13):2112. doi: 10.3390/cells11132112.
Vives J, Sòria MG, McGrath E, Magri M .
• Public Cord Blood Banks as a source of starting material for clinical grade HLA- homozygous induced pluripotent stem cells.
Stem Cell Res Ther. 2022 Aug 12;13(1):408. doi: 10.1186/s13287-022-02961-6. Álvarez-Palomo B, Veiga A, Raya A, Codinach M, Torrents S, Ponce Verdugo L, Rodrí- guez-Aierbe C, Cuéllar L, Alenda R, Arbona C, Hernández-Maraver D, Fusté C, Querol S .
• Optimisation of processing methods to improve success in the derivation of hu- man multipotent mesenchymal stromal cells from cryopreserved umbilical cord tissue fragments.
Cryobiology. 2022 Oct;108:34-41. doi: 10.1016/j.cryobiol.2022.08.002. Muñoz-Domínguez N, Carreras-Sánchez I, López-Fernández A, Vives J .
• CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.
Front Immunol. 2022 Jul 6;13:904497. doi: 10.3389/fimmu.2022.904497.
Caballero AC, Escribà-García L, Álvarez-Fernández C, Briones J .
172